HGH 191AA (Somatropin)
FDA ApprovedSingle-chain polypeptide with two disulfide bridges
Somatropin (HGH 191AA) is a recombinant human growth hormone consisting of 191 amino acids, identical in structure to the naturally produced hormone. In research settings, it has been studied for its role in growth hormone receptor signaling, IGF-1 pathway activation, and metabolic regulation. Published studies have investigated its effects on cell growth, protein synthesis, and lipid metabolism in laboratory models. RaysunPeptide manufactures and supplies HGH 191AA for qualified research and laboratory applications.
Mechanism of Action
Binds to GH receptors on target tissues, triggering JAK2-STAT5 signaling pathway. Direct effects include lipolysis, protein synthesis, and metabolic regulation. Indirect effects via IGF-1 promote growth and anabolism. Half-life ~3 hours subcutaneously.
Key Benefits
Molecular Data
Dosing Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Medical GHD (Starting) | 0.15-0.3mg/day (0.5-1 IU) | Once daily | SubQ |
| Medical GHD (Maintenance) | 0.4-0.8mg/day (1.2-2.4 IU) | Once daily | SubQ |
| Anti-Aging/Wellness | 1-2 IU/day (0.33-0.67mg) | Once daily | SubQ |
| Body Recomposition | 2-4 IU/day (0.67-1.33mg) | Once or twice daily | SubQ |
| Performance (Higher Risk) | 4-8 IU/day (1.33-2.67mg) | Split twice daily | SubQ |
Research Indications
Growth Hormone Deficiency
FDA-approved for idiopathic and organic causes, Turner syndrome, Prader-Willi syndrome, SGA, Noonan syndrome, SHOX deficiency.
FDA-approved for childhood-onset or adult-onset causes (pituitary tumors, surgery, radiation, trauma).
FDA-approved to increase lean body mass and body weight in cachexia.
Body Composition
Significant fat loss especially abdominal/visceral fat over 1-3 months.
Increased muscle mass and improved body composition.
Enhanced exercise recovery and tissue healing.
Anti-Aging
Improved skin elasticity, texture, and hair/nail growth.
Improved energy, sleep, and quality of life.
Peptide Interactions
HGH decreases insulin sensitivity; may require increased insulin doses in diabetics.
Synergistic but caution: enhanced effects with increased hypoglycemia and side effect risk.
Increases T4 to T3 conversion; unmasks hypothyroidism in 36-47% of patients.
GHRH analog can enhance effects though may be redundant with exogenous HGH.
Ghrelin mimetic works via different pathway.
Enhances natural pulsatile release.
Can unmask cortisol deficiency; replacement should precede HGH.
Commonly combined in hormone replacement therapy.
May manage insulin resistance; may reduce IGF-1 levels.
GLP-1 agonists help manage insulin resistance during HGH therapy.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Water retention and fluid accumulation
- •Joint pain and stiffness
- •Carpal tunnel syndrome (usually resolves with dose reduction)
- •Headaches
- •Numbness/tingling in hands
Stop Signs (Seek Medical Attention)
- ⚠Severe or worsening carpal tunnel symptoms
- ⚠Signs of diabetes (increased thirst, frequent urination, blurred vision)
- ⚠Severe edema (facial, hand, or feet swelling)
- ⚠Severe joint/muscle pain unresponsive to dose reduction
- ⚠New lumps, masses, or rapidly growing moles
- ⚠Severe headaches or vision changes
- ⚠Signs of allergic reaction
- ⚠Gynecomastia (breast tissue growth in males)
- ⚠Hypothyroid symptoms (fatigue, weight gain, cold intolerance)
Contraindications
- ✕Active cancer (may accelerate tumor growth)
- ✕Acute critical illness (increased mortality in ICU patients)
- ✕Closed epiphyses in children (for growth promotion)
- ✕Pregnancy/breastfeeding
Quality Checklist
Good Signs ✓
- White to off-white lyophilized powder or solid cake (not liquid/collapsed)
- Crystal clear reconstituted solution with no particles
- Intact vacuum in sealed vial (resistance when inserting needle)
- Pharmaceutical grade with certificate of analysis (Genotropin, Norditropin, Humatrope preferred)
Warning Signs !
- Generic/underground lab products have highly variable quality and potency
- Common counterfeits exist; third-party testing recommended
Bad Signs ✕
- Cloudy, discolored, or particles visible indicates degradation
- Powder appears melted or stuck to vial (improper storage)
- Yellow/brown coloring
References
15,809 patients from the KIMS database, mean 5.3 years follow-up. Adverse events in 51.2% of patients, treatment-related in 18.8%. No correlation between GH dose and adverse event rate. Supports long-term safety of GH replacement in adults with GHD.
View on PubMed →Systematic review demonstrating positive effects of GH treatment on cardiovascular disease and fracture risk, improvements in body composition, muscle strength, quality of life, bone mass/density, and lipoprotein patterns.
View on PubMed →GH deficiency is associated with several cardiovascular risk factors that significantly increase cardiovascular morbidity and mortality. GH replacement improves cardiovascular risk factors.
View on PubMed →In 84 apparently euthyroid patients, 30 (36%) developed hypothyroidism requiring T4 therapy after starting GH. Highest risk in patients with organic pituitary disease or multiple pituitary hormone deficiencies.
View on PubMed →FAQs
